ArticleVaccine2012
The potential economic value of a human norovirus vaccine for the United States.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review.BMC infectious diseases · 2015Pooled it
- The burden of norovirus disease in children in the European Union.The Pediatric infectious disease journal · 2015Pooled it
- Systematic review of the economic value of diarrheal vaccines.Human vaccines & immunotherapeutics · 2014Pooled it
- Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant.Frontiers in immunology · 2023Trial
- A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.Frontiers in immunology · 2022Trial
- Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.The Journal of infectious diseases · 2016Trial
- Serological Correlates of Protection against a GII.4 Norovirus.Clinical and vaccine immunology : CVI · 2015Trial
- Persistence of the Immune Response to an Intramuscular Bivalent (GI.1/GII.4) Norovirus Vaccine in Adults.Vaccines · 2025Article
- Household economic costs of norovirus gastroenteritis in two community cohorts in Peru, 2012-2019.PLOS global public health · 2024Article
- Vaccine value profile for norovirus.Vaccine · 2023Article
- An Overview of the Public Health Challenges in Diagnosing and Controlling Human Foodborne Pathogens.Vaccines · 2023Review
- Review
- Epidemiology and evolution of Norovirus in China.Human vaccines & immunotherapeutics · 2021Review
- A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus.Journal of virological methods · 2021Article
- Norovirus Protease Structure and Antivirals Development.Viruses · 2021Review
- Burden of Norovirus in the United States, as Estimated Based on Administrative Data: Updates for Medically Attended Illness and Mortality, 2001-2015.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Article
- Potential Clinical and Economic Value of Norovirus Vaccination in the Community Setting.American journal of preventive medicine · 2021Article
- Recent advances in human norovirus research and implications for candidate vaccines.Expert review of vaccines · 2020Review
- Human Norovirus Cultivation in Nontransformed Stem Cell-Derived Human Intestinal Enteroid Cultures: Success and Challenges.Viruses · 2019Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Vaccines against human norovirus are currently under development. We developed a simulation model to determine their potential economic value. Vaccination prevented 100-6125 norovirus gastroenteritis cases per 10,000 vaccinees. Low vaccine cost (≤$50) garnered cost-savings and a more expensive vaccine led to costs per case averted comparable to other vaccines. In the US, vaccination could avert approximately 1.0-2.2 million cases (efficacy 50%, 12 month duration), costing an additional $400 million to $1.0 billion, but could save ≤$2.1 billion (48 month duration). Human norovirus vaccination can offer economic value while averting clinical outcomes, depending on price, efficacy, and protection duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.